Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Farhad Ravandi, MD, Alfonso Quintas-Cardama, MD, Elias J. Jabbour, MD, Charles Asa Koller, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Elizabeth M Burton, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 3617.

https://doi.org/10.1182/blood.V120.21.3617.3617

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

Journal Articles

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Kiran Naqvi, MD, Hagop M Kantarjian, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, Susan O'Brien, MD, Elizabeth M Burton, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, William G. Wierda, MD, PhD, Gautam Borthakur, Alfonso Quintas-Cardama, MD, Jorge E. Cortes

Blood (2011) 118 (21): 3784.

https://doi.org/10.1182/blood.V118.21.3784.3784

Published: 2011

Journal Articles

Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,

Asifa Malik, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan o'Brien, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Deborah A. Thomas, MD, Elizabeth M Burton, Elias Jabbour, Jorge E. Cortes

Blood (2011) 118 (21): 3786.

https://doi.org/10.1182/blood.V118.21.3786.3786

Published: 2011

Journal Articles

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Maro Ohanian, DO, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Elizabeth M Burton, Long Xuan Trinh, Alessandra Ferrajoli, MD, Elias Jabbour, Tapan Kadia, Jorge E. Cortes

Blood (2011) 118 (21): 3779.

https://doi.org/10.1182/blood.V118.21.3779.3779

Published: 2011

Journal Articles

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, MD, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O’Brien, Jorge E. Cortes

Blood (2011) 118 (21): 4443.

https://doi.org/10.1182/blood.V118.21.4443.4443

Published: 2011

Journal Articles

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Theresa Liu-Dumlao, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Elias Jabbour, Jan A. Burger, MD, PhD, Yesid Alvarado, MD, Elizabeth M Burton, Long Xuan Trinh, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 2761.

https://doi.org/10.1182/blood.V118.21.2761.2761

Published: 2011

Journal Articles

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, MD, Elizabeth M Burton, Gautam Borthakur, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Marina Konopleva, M.D., Ph.D., Jan A. Burger, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 745.

https://doi.org/10.1182/blood.V118.21.745.745

Published: 2011

Journal Articles

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Mahran Shoukier, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, Zeev Estrov, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Steven M. Kornblau, Elizabeth M Burton, Susan O'Brien, Jorge E Cortes

Blood (2011) 118 (21): 2764.

https://doi.org/10.1182/blood.V118.21.2764.2764

Published: 2011

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, Gautam Borthakur, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William G. Wierda, Elizabeth M Burton, Jorge Cortes

Blood (2008) 112 (11): 2111.

https://doi.org/10.1182/blood.V112.11.2111.2111

Published: 2008

Journal Articles

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Dushyant Verma, MD, FACP, Hagop M. Kantarjian, MD, Mary Beth Rios, Susan O’Brien, MD, Pat Ault, Elizabeth M. Burton, Zeev Estrov, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Jorge Cortes, MD

Blood (2008) 112 (11): 2125.

https://doi.org/10.1182/blood.V112.11.2125.2125

Published: 2008

NARROW

Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP),

Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome,

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only